Liver Transplantation - Pipeline Review, H1 2016

  • ID: 3714985
  • Report
  • 78 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • Novartis AG
  • RedHill Biopharma Ltd.
  • MORE
Liver Transplantation - Pipeline Review, H1 2016

Summary

‘Liver Transplantation - Pipeline Review, H1 2016’, provides an overview of the Liver Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Transplantation and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Transplantation
- The report reviews pipeline therapeutics for Liver Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Transplantation therapeutics and enlists all their major and minor projects
- The report assesses Liver Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Liver Transplantation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Liver Transplantation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • Novartis AG
  • RedHill Biopharma Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Liver Transplantation Overview

Therapeutics Development

Pipeline Products for Liver Transplantation - Overview

Pipeline Products for Liver Transplantation - Comparative Analysis

Liver Transplantation - Therapeutics under Development by Companies

Liver Transplantation - Therapeutics under Investigation by Universities/Institutes

Liver Transplantation - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Liver Transplantation - Products under Development by Companies

Liver Transplantation - Products under Investigation by Universities/Institutes

Liver Transplantation - Companies Involved in Therapeutics Development

Astellas Pharma Inc.

Conatus Pharmaceuticals Inc.

Digna Biotech, S.L.

Dompe Farmaceutici S.p.A.

Novartis AG

RedHill Biopharma Ltd.

Liver Transplantation - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ABC-294640 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cardiotrophin-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Liver Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Liver Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FX-06 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

reparixin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tacrolimus ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TR-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Liver Transplantation - Recent Pipeline Updates

Liver Transplantation - Dormant Projects

Liver Transplantation - Discontinued Products

Liver Transplantation - Product Development Milestones

Featured News & Press Releases

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients

Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting

Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules

Oct 20, 2011: European Medicines Agency Agrees To Precautionary Recall Of Advagraf 0.5mg Capsule Batches

Jul 01, 2011: Astellas Introduces Advagraf In India

Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I

Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant

Oct 02, 2007: New Once-Daily Advagraf Launched Across Europe.

Jun 18, 2007: Advagraf Now Available in Germany and the UK as a Once-Daily Immunosuppressant in Organ Transplantation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Liver Transplantation, H1 2016

Number of Products under Development for Liver Transplantation - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Liver Transplantation - Pipeline by Astellas Pharma Inc., H1 2016

Liver Transplantation - Pipeline by Conatus Pharmaceuticals Inc., H1 2016

Liver Transplantation - Pipeline by Digna Biotech, S.L., H1 2016

Liver Transplantation - Pipeline by Dompe Farmaceutici S.p.A., H1 2016

Liver Transplantation - Pipeline by Novartis AG, H1 2016

Liver Transplantation - Pipeline by RedHill Biopharma Ltd., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Liver Transplantation Therapeutics - Recent Pipeline Updates, H1 2016

Liver Transplantation - Dormant Projects, H1 2016

Liver Transplantation - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Liver Transplantation, H1 2016

Number of Products under Development for Liver Transplantation - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Astellas Pharma Inc.
Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Dompe Farmaceutici S.p.A.
Novartis AG
RedHill Biopharma Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll